Knight Therapeutics and Sumitomo Pharma Enter into Exclusive Licensing Agreements to Commercialize Sumitomo?S Canadian Portfolio

Published: 2025-06-05 08:20:53 ET GUD.TO

Published on 06/05/2025 at 08:20

Knight Therapeutics Inc. and Sumitomo Pharma America Inc. announced that Knight and SMPA?s affiliates have entered into exclusive license and supply agreements to commercialize MYFEMBREE® (relugolix/estradiol/norethindrone acetate), ORGOVYX® (relugolix) and vibegron in Canada, as well as an asset purchase agreement under which Knight will acquire certain mature products (the ?Mature Products?, together with MYFEMBREE®, ORGOVYX® and vibegron, the ?Products?). For the year ended March 2025, the Products generated CAD 11.2 million in revenue. Under the terms of the agreements, Knight will have the exclusive rights to distribute, promote, market and sell the Products in Canada.

Knight will begin commercial activities following a transition period from Sumitomo Pharma Canada. The consideration for the transaction includes an upfront amount of CAD 25.4 million and Knight may pay future contingent payments of up to CAD 15.75 million upon achieving certain sales milestones. In addition, Knight is expected to pay an estimated CAD 7 million for inventory to be acquired over the next eight months.